Acceleron Pharma Inc - Company Profile

Powered by

All the data and insights you need on Acceleron Pharma Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Acceleron Pharma Inc Strategy Report

  • Understand Acceleron Pharma Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Acceleron Pharma Inc: Overview

Select Item

Acceleron Pharma Inc (Acceleron) is a clinical stage biopharmaceutical company that discovers, develops and commercializes drugs to treat serious and rare diseases. Reblozyl is the company’s only commercial product used for the treatment of transfusion-dependent anemia patients with beta thalassemia and myelodysplastic syndromes (MDS). The company’s lead therapeutic candidate, luspatercept-aamt is in clinical trials for the treatment of anemia and associated complications in myelodysplastic syndromes, and myelofibrosis. Its other pipeline products are being evaluated for the treatment of lung disease. The company has operations in the US, Bermuda and Switzerland. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Acceleron Pharma Inc and make more informed decisions for your business Gain a 360-degree view of Acceleron Pharma Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 128 Sidney St, Cambridge, Massachusetts, 02139-4239
Website www.acceleronpharma.com
Telephone 1 617 6499200
No of Employees 312
Industry Pharmaceuticals and Healthcare
Revenue (2020) $92.5M
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Acceleron Pharma Inc premium industry data and analytics

30+

Clinical Trials

Determine Acceleron Pharma Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

30+

Catalyst Calendar

Proactively evaluate Acceleron Pharma Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Acceleron Pharma Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

Products and Services

Products
Commercial:
Reblozyl (luspatercept-aamt)- for anemia with beta-thalassemia and myelodysplastic syndromes patients.
Pipeline Product:
XYZ
XYZ
XYZ
Understand Acceleron Pharma Inc portfolio and identify potential areas for collaboration Understand Acceleron Pharma Inc portfolio and identify potential areas for collaboration Find out more
Image for loader
Executives
Name Position Board Since Age
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Acceleron Pharma Inc key executives to enhance your sales strategy Gain insight into Acceleron Pharma Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward